Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364377 · ClinicalTrials.gov registry record · Phase 4
Incretins in Impaired Fasting Glucose
A Phase 4 study of Pre Diabetes, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00364377 is a Phase 4 study of Pre Diabetes that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00364377, a Phase 4 study of Pre Diabetes, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hormone, called glucagon-like peptide-1 (GLP-1), is normally released by the intestine in response to the presence of food. This hormone acts like a messenger between the intestine and the pancreas to raise insulin levels, and therefore, lower blood sugars. Sitagliptin is effective in people with diabetes, however, this study is being done to determine if Sitagliptin is effective in people with high fasting glucose who do not yet have diabetes.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sitagliptin
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364377
The ClinicalTrials.gov registry entry for NCT00364377 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 59 other Pre Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pre Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00364377 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00364377 about?
NCT00364377 is a clinical study titled "Incretins in Impaired Fasting Glucose". People with high fasting glucose can develop type 2 diabetes with the passage of time. This study is being done to determine the effect of a novel medication in people with this elevated fasting glucose. Sitagliptin is a substance that raises levels of a hormone normally found in the blood. This hor...
What is the current status of trial NCT00364377?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2006-08. Estimated completion is 2008-12.
What conditions does trial NCT00364377 study?
This clinical trial studies the following conditions: Pre Diabetes.
What interventions are being tested in trial NCT00364377?
The interventions under investigation include: Placebo (OTHER), Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT00364377?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00364377 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
RECRUITING · Phase 4
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
RECRUITING · NA
-
Glycemic Metrics and Patterns in People With and Without Prediabetes
RECRUITING
-
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.